Zacks cuts Gilead earnings estimate to USD 2.14 for Gilead Sciences stock
Published on 10/05/2026 at 09:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead Sciences stock is at EUR 128.86 at Lang & Schwarz on October 5, 2026 at 9:18 a.m. CEST, up 0.20 percent from the EUR 128.60 prior close. The immediate company catalyst is an analyst estimate cut: according to MarketBeat on October 1, 2026, Zacks Research lowered its first-quarter 2028 earnings-per-share estimate to USD 2.14 from USD 2.15 and kept a Hold rating.
Estimate cut meets strong revenue
The adjustment is modest in absolute terms, but it contrasts with the operating figures from Gilead's second quarter of 2026. MarketBeat reported revenue of USD 7.80 billion against consensus of USD 7.40 billion, while earnings per share came in at negative USD 6.75 versus a negative USD 7.25 consensus estimate. Revenue therefore exceeded consensus by USD 0.40 billion, and year-over-year revenue growth reached 10.60 percent.
The earnings-per-share comparison needs context because the reported quarter included a large negative result, while the prior-year quarter produced USD 2.01 per share. For investors, the more durable signal is the combination of revenue growth and the analyst debate over how quickly the HIV franchise can offset pressure elsewhere in the portfolio.
Guidance points to a broader test
Gilead's product-sales outlook is now USD 30.1 billion to USD 30.4 billion for 2026, while product sales excluding Veklury are expected at USD 29.8 billion to USD 30.1 billion, according to Yahoo Finance in a September 28, 2026 report. That range makes execution outside the core HIV business an important measure of whether the sales expansion can persist.
The company website describes a pipeline spanning virology, oncology and inflammation, with more than 25 medicines offered globally and 53 clinical programs. Gilead Sciences also highlights once-yearly lenacapavir as a manufacturing and supply-planning priority if approved, adding a pipeline dimension to the revenue discussion.
Euro quote remains near the annual high
Gilead's primary listing is on Nasdaq, where the stock closed at USD 144.74 on October 2, 2026 at 4:00 p.m. EDT. The Nasdaq range was USD 109.66 to USD 157.29 over the prior 52 weeks, while market capitalization stood at USD 179.5 billion on October 5, 2026. In the German trading perspective, the Lang & Schwarz quote was EUR 128.86, with the EUR 128.60 prior close providing the daily comparison base.
The further course of trading is shown by the continuously updated real-time quote of Gilead Sciences stock.
Gilead Sciences stock facts
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- Ticker: GILD
- Primary exchange: NASDAQ
- Price Lang & Schwarz as of October 5, 2026, 9:18 a.m. CEST: EUR 128.86
- Change versus prior close: plus 0.20 percent
- Prior close Lang & Schwarz September 30, 2026: EUR 128.60
- Market capitalization: USD 179.5 billion as of October 5, 2026
- 52-week range: USD 109.66-157.29 as of October 5, 2026
- Sector / Industry: Healthcare / Drug Manufacturers - General
